Protia Wins 2023 Trade Day 'Tower of Million Exports'
Exports to more than 60 countries, including Europe and Southeast Asia, multi-diagnosis allergy kits
Growing every year with "PROTIA Allergy-Q" at the forefront

Protia (303360, former Proteomtech Inc.), a company specializing in in vitro diagnostic medical devices, won the "3 million dollar export tower" at the "60th 2023 Trade Day Celebration" organized by the Korea International Trade Association.

The Export Tower is an award given by the Korea International Trade Association to companies that have contributed to increasing exports for one year, and is given to corporations and people of merit who achieve new results every year. Protia renews its export performance every year, winning the million export tower this year following the tpf=board/list&board_code=17 million export tower in 2022.

As a result of expanding the number of countries and sales agencies through steady efforts over the past six years, Protia has been exporting products to more than 60 countries around the world, and is expanding its influence in overseas markets with "PROTIA Allergy-Q," an allergy multi-diagnosis product that combines "patent technology that can measure the world's most types of allergies at once."

Allergic diseases are rapidly increasing due to changes in the living environment caused by social and economic growth around the world, and interest in allergic diagnosis is also increasing. Although skin response tests, the traditional allergy test method, have been used for the past 100 years, the test method is being replaced by multiple allergen simulant test (MAST) due to various inconveniences. Protea is targeting the global market with the Protea Allergy-Cue 128M, which can test up to two to three times more allergic antigens than other competitors' products in line with the current global market trend.


In addition, the company explains that it has technology that can extract, cultivate, produce, and refine more than 320 types of allergic antigen substances on its own, so it can respond flexibly to market demands, and because it has a technological differentiation that can develop allergy-diagnosed products tailored to each country and continent, customized sales are also possible. And, as the pet market is expanding around the world, it plans to expand its overseas market further in the future with new products such as "Anitia," a pet allergy diagnosis product that can quickly and accurately identify allergy-causing substances with a small amount of serum, "Protia ANA Profile," which can diagnose autoimmune diseases, and "Protia AST," which can drastically shorten the antibiotic susceptibility test time and test 37 antibiotic items simultaneously with 192 channel tests.

"When we won the first Export Tower (tpf=board/list&board_code=17 million) last year, we expressed our ambition to continue growing so that we can win the Export Tower in the future. This time again, we are very happy to win the second consecutive export record," the president Dr. Lim said. "We will continue to target the global market with next-generation new products incorporating Protia's outstanding technology so that we can win the Export Tower every year."